Education
About Us
Working with TipRanks
Follow Us
Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
Total Valuation
Milestone Pharmaceuticals has a market cap or net worth of $143.64M. The enterprise value is $141.75M.
Market Cap$143.64M
Enterprise Value$141.75M
Share Statistics
Milestone Pharmaceuticals has 84,994,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding84,994,260
Owned by Insiders1.00%
Owned by Institutions10.79%
Financial Efficiency
Milestone Pharmaceuticals’s return on equity (ROE) is -3.16 and return on invested capital (ROIC) is -61.07%.
Return on Equity (ROE)-3.16
Return on Assets (ROA)-0.55
Return on Invested Capital (ROIC)-61.07%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee0.00
Profits Per Employee-1.26M
Employee Count33
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Milestone Pharmaceuticals is ―. Milestone Pharmaceuticals’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value11.17
Price to FCF―
Price to Operating Cash Flow-3.28
PEG Ratio―
Income Statement
In the last 12 months, Milestone Pharmaceuticals had revenue of 0.00 and earned -41.52M in profits. Earnings per share was -0.67.
Revenue0.00
Gross Profit-646.00K
Operating Income-42.10M
Pretax Income-41.78M
Net Income-41.52M
EBITDA-42.10M
Earnings Per Share (EPS)-0.67
Cash Flow
In the last 12 months, operating cash flow was -40.40M and capital expenditures -26.05K, giving a free cash flow of -40.42M billion.
Operating Cash Flow-40.40M
Free Cash Flow-40.42M
Free Cash Flow per Share-0.48
Dividends & Yields
Milestone Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.16
52-Week Price Change27.46%
50-Day Moving Average1.71
200-Day Moving Average1.70
Relative Strength Index (RSI)61.48
Average Volume (3m)1.19M
Important Dates
Milestone Pharmaceuticals upcoming earnings date is Nov 12, 2025, Before Open (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 12, 2025
Ex-Dividend Date―
Financial Position
Milestone Pharmaceuticals as a current ratio of 9.10, with Debt / Equity ratio of -907.84%
Current Ratio9.10
Quick Ratio9.10
Debt to Market Cap0.37
Net Debt to EBITDA-0.70
Interest Coverage Ratio11.76
Taxes
In the past 12 months, Milestone Pharmaceuticals has paid -259.00K in taxes.
Income Tax-259.00K
Effective Tax Rate<0.01
Enterprise Valuation
Milestone Pharmaceuticals EV to EBITDA ratio is -4.19, with an EV/FCF ratio of -6.10.
EV to Sales0.00
EV to EBITDA-4.19
EV to Free Cash Flow-6.10
EV to Operating Cash Flow-6.11
Balance Sheet
Milestone Pharmaceuticals has $43.42M in cash and marketable securities with $56.39M in debt, giving a net cash position of $12.98M billion.
Cash & Marketable Securities$43.42M
Total Debt$56.39M
Net Cash$12.98M
Net Cash Per Share$0.15
Tangible Book Value Per Share$0.21
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Milestone Pharmaceuticals is $4.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.50
Price Target Upside148.62% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast20.13%